News & media
rBIO news and updates.
Follow rBIO’s progress as the company advances its proprietary manufacturing process, insulin-first licensing strategy, and scale-up plan.
Latest coverage
-
Why GLP-1 drugs won’t replace insulin in diabetes care
Read more →: Why GLP-1 drugs won’t replace insulin in diabetes care -
BioPharma APAC: R-biolin matches Novolin R in pre-clinical tests, gears up for 50× scale-up and human trials
Read more →: BioPharma APAC: R-biolin matches Novolin R in pre-clinical tests, gears up for 50× scale-up and human trials -
As major insulin producers shift focus, rBIO steps up to address potential shortages
Read more →: As major insulin producers shift focus, rBIO steps up to address potential shortages -
FirstWord Pharma: rBIO steps in as big insulin makers scale back legacy products
Read more →: FirstWord Pharma: rBIO steps in as big insulin makers scale back legacy products -
BioProcess Online: The path to producing an insulin biosimilar
Read more →: BioProcess Online: The path to producing an insulin biosimilar -
WIRED: Can a tiny biotech make insulin dirt-cheap?
Read more →: WIRED: Can a tiny biotech make insulin dirt-cheap?
Media inquiries
Connect with rBIO.
For company information, interview requests, partnerships or investor inquiries, contact the rBIO team.